This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raafat, A. M. Articles by Haslam, S. Z. Search for Related Content PubMed PubMed Citation Articles by Raafat, A. M. Articles by Haslam, S. Z.

A Mouse Model to Study the Effects of Hormone Replacement Therapy on Normal Mammary Gland during Menopause: Enhanced Proliferative Response to Estrogen in Late Postmenopausal Mice¹

Department of Physiology, Michigan State University, East Lansing, Michigan 48824

Address all correspondence and requests for reprints to: Sandra Z. Haslam, Ph.D., Department of Physiology, 108 Giltner Hall, Michigan State University, East Lansing, Michigan 48824. E-mail: shaslam{at}pilot.msu.edu

Hormone replacement therapy (HRT) with estrogen alleviates menopausal symptoms and is effective in reducing osteoporosis and cardiovascular disease when taken in early postmenopause. Older, late postmenopausal women who never previously received HRT are also believed to benefit from estrogen treatment. On the other hand, increased lifetime exposure of the mammary gland to estrogen may increase the risk of breast cancer. The development of suitable experimental animal model systems can advance our understanding of the effects of estrogen and the timing of HRT on the postmenopausal breast. Toward this end, early and late postmenopausal states were induced in mice by short vs. long term ovariectomy (1 vs. 5 weeks), and the effects of 17ß-estradiol (E) on mammary gland morphology, cell proliferation, and progesterone receptor (PR) levels were investigated. We report that in late postmenopausal mice, E caused a pronounced enlargement of duct ends and 6.5- and 4-fold greater mitogenic responses in the duct end epithelium and adjacent stromal cells, respectively, compared with the response in early postmenopausal mice. Furthermore, after long term, daily treatment with E, steady state levels of proliferation remained 2-fold higher than those of similarly treated, early postmenopausal mice. E failed to increase mammary PR levels in late postmenopausal, but not in early postmenopausal mice. Stimulation of duct ends by E and lack of PR inducibility are characteristics of the immature pubertal mammary gland and indicate that the late postmenopausal mammary gland resembled the immature state. In contrast, minimal E-induced proliferation and increased PR inducibility, characteristics of the adult, sexually mature mammary gland, were retained in early postmenopausal mice. The lack of difference in the numbers of estrogen receptor-positive epithelial or stromal cells or in estrogen receptor cellular concentration after short vs. long term ovariectomy indicates that the observed greater efficacy of E is mediated at a step beyond receptor-ligand binding. This mouse model of experimentally induced early vs. late postmenopausal states should prove useful in better understanding alterations in hormone responsiveness and their implications for timing of HRT on the human breast.

This article has been cited by other articles:

				K. Britt, A. Ashworth, and M. Smalley Pregnancy and the risk of breast cancer Endocr. Relat. Cancer, December 1, 2007; 14(4): 907 - 933. [Abstract] [Full Text] [PDF]

				S. Shantakumar, M. B. Terry, A. Paykin, S. L. Teitelbaum, J. A. Britton, P. G. Moorman, S. B. Kritchevsky, A. I. Neugut, and M. D. Gammon Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk Am. J. Epidemiol., May 15, 2007; 165(10): 1187 - 1198. [Abstract] [Full Text] [PDF]

				S. J. Han, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley Distinct Temporal and Spatial Activities of RU486 on Progesterone Receptor Function in Reproductive Organs of Ovariectomized Mice Endocrinology, May 1, 2007; 148(5): 2471 - 2486. [Abstract] [Full Text] [PDF]

				Y. Ma, P. Katiyar, L. P. Jones, S. Fan, Y. Zhang, P. A. Furth, and E. M. Rosen The Breast Cancer Susceptibility Gene BRCA1 Regulates Progesterone Receptor Signaling in Mammary Epithelial Cells Mol. Endocrinol., January 1, 2006; 20(1): 14 - 34. [Abstract] [Full Text] [PDF]

				A. W. Kurian, M. A. Mills, M. Jaffee, B. M. Sigal, N. M. Chun, K. E. Kingham, L. C. Collins, K. W. Nowels, S. K. Plevritis, J. E. Garber, et al. Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1082 - 1089. [Abstract] [Full Text] [PDF]

				G. Cheng, Z. Weihua, M. Warner, and J.-A. Gustafsson Inaugural Article: Estrogen receptors ER{alpha} and ER{beta} in proliferation in the rodent mammary gland PNAS, March 16, 2004; 101(11): 3739 - 3746. [Abstract] [Full Text] [PDF]

				E. L. Milliken, R. K. Ameduri, M. D. Landis, A. Behrooz, F. W. Abdul-Karim, and R. A. Keri Ovarian Hyperstimulation by LH Leads to Mammary Gland Hyperplasia and Cancer Predisposition in Transgenic Mice Endocrinology, September 1, 2002; 143(9): 3671 - 3680. [Abstract] [Full Text] [PDF]

				J. Fiorica, C. M. Rutter, M. T. Mandelson, S. Taplin, and M. B. Laya Association Between Changes in Hormone Replacement Therapy and Breast Density JAMA, April 11, 2001; 285(14): 1839 - 1840. [Full Text] [PDF]

				G. G. Geary, D. N. Krause, and S. P. Duckles Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms Am J Physiol Heart Circ Physiol, August 1, 2000; 279(2): H511 - H519. [Abstract] [Full Text] [PDF]

				H.-Y. Li, J.-S. Bian, Y. W. Kwan, and T. M. Wong Enhanced Responses to 17beta -Estradiol in Rat Hearts Treated with Isoproterenol: Involvement of a Cyclic AMP-Dependent Pathway J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 592 - 598. [Abstract] [Full Text]